Effect of Probucol Treatment on Blood Lipid Markers(Especially Malondialdehyde-modified Low-density Lipoproteins) in Type 2 Diabetic Patients with Hypercholesterolemia.

  • Sato Noriyuki
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Kase Hiroyuki
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Suzuki Manabu
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Iijima Hideo
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Kawagoe Yoshiaki
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Matsumura Mihoko
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Motohashi Satoshi
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Atsuta Haruhiko
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Kato Tetsuya
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Mochizuki Yasuhiro
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Kanazawa Hiroki
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Kuroda Hisamoto
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Bannba Nobuyuki
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Hattori Yoshiyuki
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine
  • Kasai Kikuo
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine

Bibliographic Information

Other Title
  • プロブコール投与が高脂血症を合併した2型糖尿病患者の脂質代謝に及ぼす効果  特にMDA‐LDLの検討を中心として
  • プロブコール トウヨ ガ コウシケツショウ オ ガッペイ シタ 2ガタ トウニョウビョウ カンジャ ノ シシツ タイシャ ニ オヨボス コウカ : トクニ MDA-LDL ノ ケントウ オ チュウシン ト シテ
  • 特にMDA-LDLの検討を中心として

Search this article

Abstract

Probucol is known to have an antioxidant effect, but its effect on serum malondialdehyde-modified LDL (MDA-LDL) is unknown. We studied the effect of 3-month probucol treatment on MDA-LDL and other lipids markers [total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), lipid peroxidation (LPO), lipoprotein a (Lp (a)), and remnant-like particle cholesterol (RLP-C)] in type 2 diabetic patients with hypercholesterolemia.<BR>At the start of treatment, MDA-LDL correlated positively with LPO, TC, LDL-C, and HbA1c (p<0.05). Probucol treatment significantly reduced MDA-LDL, LPO, TC, HDL-C, and LDL-C (p<0.05), although other markers were not changed. Furthermore, % change in MDA-LDL by probucol treatment also correlated positively with % changes in both LPO and HbAic.<BR>This data suggests that probucol reduced MDA-LDL in type 2 diabetic patients. Probucol is thus useful in improving dyslipidemia quantitatively and qualitatively in type 2 diabetic patients.

Journal

References(12)*help

See more

Details

Report a problem

Back to top